Knowledge and attitudes about preexposure prophylaxis (PrEP) among sexually active men who have sex with men and who participate in new york city gay pride events

LGBT Health

Volumn 1, Issue 2, 2014, Pages 93-97

  Mantell, Joanne E ^a   Sandfort, Theo G M ^a   Hoffman, Susie ^a,b   Guidry, John A ^c   Masvawure, Tsitsi B ^a   Cahill, Sean ^d  

^a HIV Center for Clinical and Behavioral Studies   (United States)

^b Department of Medicine   (United States)

^c Independent Consultant   (United States)

^d FENWAY INSTITUTE   (United States)

Author keywords

access to care; gay; HIV AIDS; PrEP

Indexed keywords

EID: 84969255803     PISSN: 23258292     EISSN: 23258306     Source Type: Journal    
DOI: 10.1089/lgbt.2013.0047     Document Type: Article

References (12)

1. Baeten JM, Donnell D, Ndase P, Celum C: Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. NEJM 2012;367:399-419
2. Thigpen MC, Kebaabetswe PM, Paxton LA, et al.: Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. NEJM 2012;367:423-443
3. Choopanya K, Martin M, Suntharasamai P, et al.: Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (The Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2013;381:2083-2090
4. Grant RM, Lama JR, Anderson PL, et al.: Pre-exposure chemoprophylaxis for HIV prevention in men who have sex with men. NEJM 2010;363:2587-2599
5. Van Damme L, Corneli A, Ahmed K, et al.: Preexposureprophylaxis for HIV infection among African women. NEJM 2012;367:411-422
6. Marrazzo J, Ramjee G, Nair G, et al.: Pre-exposure prophylaxis for HIV in women: Daily oral tenofovir, oral tenofovir/ emtricitabine or vaginal tenofovir gel in the VOICE study (MTN 003) (2013) [Oral Presentation]. In: Pocket Program: CROI 2013: 20th Conference on Retroviruses and Opportunistic Infections.March 3-6, 2013. GeorgiaWorld Congress Center, Atlanta, GA, US (pp. 8). Alexandria, VA: CROI
7. Merck/HVTN: Vaccination and enrollment are discontinued in Phase II trials of Merck's investigational HIV vaccine candidate. Interim analysis of STEP study shows vaccine was not effective. September 21, 2007. Available at www .hvtn.org/pdf/FINAL-HIV-Vaccine-Press-Release.pdf (last accessed on May 24, 2013
8. Voetsch AC, Heffelfinger JD, Begley EM, et al.: Knowledge and use of preexposure and postexposure prophylaxis among attendees ofMinority Gay Pride events, 2005 through 2006. J Acquir Immune Defic Syndr 2007;46:378-380. (Pubitemid 350287373
9. Barash EA, Golden M: Awareness and use of HIV pre-exposure prophylaxis among attendees of a Seattle gay pride event and sexually transmitted disease clinic. AIDS Patient Care STDS 2010;24:689-691
10. US Food and Drug Administration: FDA approves first drug for reducing the risk of sexually acquired HIV infection. Available at www.fda.gov/NewsEvents/ Newsroom/PressAnnounce ments/ucm312210.htm (last accessed on May 24, 2013
11. Centers for Disease Control and Prevention: Interim guidance: Preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep 2011;60:65-68
12. Tuller D: A resisted pill to prevent H.I.V. The New York TimeS Available at www.nytimes.com/2013/12/31/health/aresisted-pill-To-prevent-hiv.html?-r= 0&pagewanted=print (last accessed on December 30, 2013